Alzheimer’s ‘wonder drug’ won’t be available on NHS because it’s too costly
The NHS spending watchdog has recommended that a ‘groundbreaking’ Alzheimer’s drug shouldn’t be made available on the NHS.
It comes just days after experts in the UK hailed it as the ‘beginning of the end’ for the devastating disease.
The National Institute for Health and Care Excellence (Nice) have now said the benefits of lecanemab are ‘just too small to justify the significant cost to the NHS.’
The drug was deemed efficient at slowing Alzheimer’s disease by the The Medicines and Healthcare products Regulatory Agency (MHRA) earlier this week.
